A Phase II Multi-institutional Trial of Chemoradiation Using Weekly Docetaxel and Erythropoietin for High-Risk Postoperative Head and Neck Cancer Patients

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 5, 2007, Pages 1323-1331

  Willey, Christopher D ^a   Murphy, Barbara A ^a   Netterville, James L ^a   Burkey, Brian B ^a   Shyr, Yu ^a   Shakhtour, Bashar ^a   Kish, Bonnie ^a   Raben, David ^b   Chen, Changhu ^c   Song, John I ^d   Kane, Madeleine A ^c   Cmelak, Anthony J ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoradiation; Clinical trial; Docetaxel; Head and neck cancer; Postoperative

Indexed keywords

DISEASES; HEALTH RISKS; HEMOGLOBIN; PATIENT MONITORING; TUMORS;

CHEMORADIATION; CLINICAL TRIALS; DOCETAXEL; HEAD AND NECK CANCER; POSTOPERATIVE;

CHEMOTHERAPY;

ANTIEMETIC AGENT; CETUXIMAB; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ERYTHROPOIETIN; FLUOROURACIL; TAXANE DERIVATIVE;

ADULT; AGED; AGEUSIA; ANEMIA; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPHAGIA; FEMALE; HEAD AND NECK CANCER; HIGH RISK PATIENT; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LYMPH NODE METASTASIS; MALE; MOUTH CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OROPHARYNX CANCER; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ERYTHROPOIETIN; FEMALE; HEAD AND NECK NEOPLASMS; HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; STOMATITIS; TAXOIDS;

EID: 33947518780     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.11.033     Document Type: Article

References (83)

1. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
2. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
3. Schiff P.B., and Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 77 (1980) 1561-1565
4. Tomiak E., Piccart M.J., Kerger J., et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12 (1994) 1458-1467
5. Burris H., Irvin R., Kuhn J., et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 11 (1993) 950-958
6. Choy H., Rodriguez F.F., Koester S., et al. Investigation of taxol as a potential radiation sensitizer. Cancer 71 (1993) 3774-3778
7. Tishler R.B., Schiff P.B., Geard C.R., et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22 (1992) 613-617
8. Hennequin C., Giocanti N., and Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 56 (1996) 1842-1850
9. Chaffey J.T., and Hellman S. Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle. Cancer Res 31 (1971) 1613-1615
10. Giannakakou P., Robey R., Fojo T., et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20 (2001) 3806-3813
11. Jordan M.A., Wendell K., Gardiner S., et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56 (1996) 816-825
12. Baker S.D., Zhao M., Lee C.K., et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 10 (2004) 1976-1983
13. Schoffski P., Weihkopf T., and Ganser A. Advanced head and neck cancer and clinical experience of an effective new agent: Docetaxel. Anticancer Res 18 (1998) 4751-4756
14. Dreyfuss A.I., Clark J.R., Norris C.M., et al. Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14 (1996) 1672-1678
15. Schoffski P., Catimel G., Planting A.S., et al. Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10 (1999) 119-122
16. Haddad R., Colevas A.D., Tishler R., et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck-The Dana Farber Cancer Institute experience. Cancer 97 (2003) 412-418
17. Posner M.R., and Lefebvre J.L. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. British J Cancer 88 (2003) 11-17
18. Nabell L., and Spencer S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol 30 (2003) 89-93
19. Vermorken J.B., Remenar E., and van H.C. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol 22 Suppl (2004) 490s-490s
20. Posner M.R. Paradigm shift in the treatment of head and neck cancer: The role of neoadjuvant chemotherapy. Oncologist 10 Suppl 3 (2005) 11-19
21. Kodaira T., Fuwa N., Furutani K., et al. Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol 35 (2005) 173-176
22. Tabernero J., Climent M.A., Lluch A., et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15 (2004) 1358-1365
23. Gervais R., Ducolone A., Breton J.L., et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16 (2005) 90-96
24. Gridelli C., Gallo C., Di Maio M., et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 91 (2004) 1996-2004
25. Lavey R.S., and Dempsey W.H. Erythropoietin increases hemoglobin in cancer-patients during radiation-therapy. Int J Radiat Oncol Biol Physics 27 (1993) 1147-1152
26. Brizel D.M., Dodge R.K., Clough R.W., et al. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53 (1999) 113-117
27. Prosnitz R.G., Yao B., Farrell C.L., et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Physics 61 (2005) 1087-1095
28. Blohmer J.U., Wurschmidt F., and Petry U. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high risk cervical cancer. Proc Am Soc Clin Oncol 22 (2003) 447
29. Shasha D., George M.J., and Harrison L.B. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 98 (2003) 1072-1079
30. Rades D., Schild S.E., Yekebas E.F., et al. Epoetin-alpha during radiotherapy for stage III esophageal carcinoma. Cancer 103 (2005) 2274-2279
31. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
32. Dobrowsky W., Naude J., Widder J., et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys 42 (1998) 803-806
33. Dobrowsky W., and Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 57 (2000) 119-124
34. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16 (1998) 1318-1324
35. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
36. Calais G., Bardet E., Sire C., et al. Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys 58 (2004) 161-166
37. El-Sayed S., and Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 14 (1996) 838-847
38. Munro A.J. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71 (1995) 83-91
39. Bourhis J., and Pignon J.P. Meta-analyses in head and neck squamous cell carcinoma. What is the role of chemotherapy?. Hematol Oncol Clin North Am 13 (1999) 769-775 vii
40. Pignon J.P., Bourhis J., Domenge C., et al., MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
41. Pignon J.P., Baujat B., and Bourhis J. [Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?]. Cancer Radiother 9 (2005) 31-36 [In French]
42. Bernier J., and Cooper J.S. Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence?. Oncologist 10 (2005) 215-224
43. Glantz M.J., Choy H., Kearns C.M., et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14 (1996) 600-609
44. Brockstein B., Haraf D.J., Stenson K., et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 16 (1998) 735-744
45. Vokes E.E., Mauer A.M., Hoffman P.C., et al. Combined modality therapy in non-small cell lung and esophageal cancer: A phase I dose-escalation study of docetaxel with concurrent radiotherapy. Semin Oncol 25 (1998) 28-32
46. Formenti S.C., Symmans W.F., Volm M., et al. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 9 (1999) 34-42
47. Choy H., Safran H., Akerley W., et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4 (1998) 1931-1936
48. Koukourakis M.I., Kourousis C., Kamilaki M., et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 34 (1998) 838-844
49. Mauer A.M., Masters G.A., Haraf D.J., et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16 (1998) 159-164
50. Colevas A.D., Busse P.M., Norris C.M., et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A Phase I/II trial. J Clin Oncol 16 (1998) 1331-1339
51. Colevas A.D., Norris C.M., Tishler R.B., et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17 (1999) 3503-3511
52. Posner M.R., Glisson B., Frenette G., et al. Multicenter Phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19 (2001) 1096-1104
53. Colevas A.D., Norris C.M., Tishler R.B., et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 25 (2002) 153-159
54. Shin D.M., Glisson B.S., Khuri F.R., et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95 (2002) 322-330
55. Dunphy F.R., Dunleavy T.L., Harrison B.R., et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 and 1999. Cancer 91 (2001) 940-948
56. Haddad R., Tishler R.B., Norris C.M., et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 8 (2003) 35-44
57. Hitt R., Lopez-Pousa A., Martinez-Trufero J., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23 (2005) 8636-8645
58. Allal A.S., Zwahlen D., Becker M., et al. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer. Cancer J 12 (2006) 63-68
59. Tishler R.B., Norris Jr. C.M., and Colevas A.D. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 95 (2002) 1472-1481
60. Fujii M., Tsukuda M., Satake B., et al. Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 9 (2004) 107-112
61. Kovacs A.F. Maximized combined modality treatment of an unselected population of oral and oropharyngeal cancer patients. Final results of a pilot study compared with a treatment-dependent prognosis index. J Craniomaxillofac Surg 34 (2006) 74-84
62. Kovacs A.F., Schiemann M., and Turowski B. Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel-three year results of a pilot study. J Craniomaxillofac Surg 30 (2002) 112-120
63. Suzuki M., Nishimura Y., Nakamatsu K., et al. Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Jpn J Clin Oncol 33 (2003) 297-301
64. Kovacs A.F., Mose S., Bottcher H.D., et al. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol 181 (2005) 26-34
65. Tishler R.B., Posner M.R., Norris Jr. C.M., et al. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 65 (2006) 1036-1044
66. Posner M.R., Colevas A.D., and Tishler R.B. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol 27 (2000) 13-24
67. Janinis J., Papadakou M., Panagos G., et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 24 (2001) 227-231
68. Hitt R., Amador M.L., Quintela-Fandino M., et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer 106 (2006) 106-111
69. Mote P.A., Davey M.W., Davey R.A., et al. Paclitaxel sensitizes multidrug resistant cells to radiation. Anticancer Drugs 7 (1996) 182-188
70. Riese N.E., Buswell L., Noll L., et al. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial. Int J Radiat Oncol Biol Phys 39 (1997) 855-858
71. Lee W.R., Berkey B., Marcial V., et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Physics 42 (1998) 1069-1075
72. Fein D.A., Lee W.R., Hanlon A.L., et al. Pretreatment hemoglobin level influences local-control and survival of T1-T2 squamous-cell carcinomas of the glottic larynx. J Clinical Oncol 13 (1995) 2077-2083
73. Overgaard J., Hansen H.S., Jorgensen K., et al. Primary radiotherapy of larynx and pharynx carcinoma-an analysis of some factors influencing local-control and survival. Int J Radiat Oncol Biol Physics 12 (1986) 515-521
74. Cortesi E., Gascon P., Henry D., et al. Standard of care for cancer-related anemia: Improving hemoglobin levels and quality of life. Oncology 68 Suppl 1 (2005) 22-32
75. Hudis C.A., Van Belle S., Chang J., et al. rHuEPO and treatment outcomes: The clinical experience. Oncologist 9 Suppl 5 (2004) 55-69
76. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
77. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4 (2003) 459-460
78. Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 (2001) 2865-2874
79. Varlotto J., and Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 63 (2005) 25-36
80. Biete Sola A., Calvo Manuel F.A., Clavo Varas B., et al. Erythropoietin in cancer treatment: considerations about Henke's article. Clin Transl Oncol 7 (2005) 332-335
81. Kaanders J.H., and van der Kogel A.J. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363 (2004) 78-79 author reply 81-72
82. Leyland-Jones B., and Mahmud S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363 (2004) 80 author reply 81-82
83. Machtay M., Pajak T., Suntharalingam M., et al. Definitive radiotherapy +/- erythropoietin for squamous cell carcinoma of the head and neck: Preliminary report of RTOG 99-03. Int J Radiat Oncol Biol Physics 60 (2004) S132-S132